Immunotherapy in genitourinary cancers
Monday, March 23, 2015
Mark A. Rubin, M.D., director of Weill Cornell's Institute for Precision Medicine, talks to Targeted Oncology about immunotherapy in the field of genitourinary cancers.
Mark A. Rubin, M.D., director of Weill Cornell's Institute for Precision Medicine, talks to Targeted Oncology about immunotherapy in the field of genitourinary cancers.